(Alliance News) - Renalytix PLC on Friday said that the US Patent Office allowed its patent clams for intellectual property exclusively licensed to the company. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More
(Alliance News) - Renalytix PLC on Tuesday said the US Centers for Medicare & Medicaid services have published the price for kidneyintelX.dkd test. Read More
Renalytix PLC - London-based kidney health-focused diagnostics company - In the financial year to June 30, pretax loss narrows to USD46.2 million from USD49.6 million a year prior. Revenue grows 13% to USD3.4 million from USD3.0 million. Says that during financial 2023, over 5,000 KidneyIntelX tests were performed, up 55% annually. "We expect a meaningful increase in total tests during the remainder of fiscal 2024, building on quarterly test volumes of about 1,200 during fiscal 2023 and through first quarter of 2024. More than half of these during the first quarter of 2024 thus far are revenue generating, with a set of the Mount Sinai clinical trial tests no longer billable following last spring's transition to full commercial payment at the hospital system," the company says. Read More
Renalytix PLC - London-based kidney health-focused diagnostics company - Says it has signed a contract with BlueCross and BlueShield of Texas to expand insurance coverage of KidneyIntelX in the state of Texas. Adds that it has executed a contract with Parkland Community Health Plan, a Dallas based insurance plan with over 300,000 covered lives and service in 7 counties, for insurance coverage of KidneyIntelX. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Renalytix PLC on Monday said its laboratory developed test KidneyIntelX has been included in a draft guidance by Kidney Disease Improving Global Outcomes, a kidney disease-focused organisation. Read More
(Alliance News) - Stock prices in London were mixed at midday on Friday, after a strong set of UK retail figures thanks to June's good weather was somewhat clouded by a fall in consumer confidence during the month of July. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
(Alliance News) - Renalytix PLC on Friday said it signed a deal with Vector Pharma FZCO for the distribution of its kidneyintelX.dkd testing in the Middle East. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
(Alliance News) - Renalytix PLC on Friday said the US Food & Drug Administration has granted marketing authorisation for its KidneyIntelX.dkd prognostic testing platform. Read More
(Alliance News) - European markets opened higher on Friday, shaking off weak economic data from China and instead taking heart from stronger economic growth from the US. Read More
(Alliance News) - Renalytix PLC on Friday said its net loss for the three months ended March 30 narrowed amid cuts in administrative costs. Read More
Renalytix PLC - London-based kidney health-focused diagnostics company - Announces partnership with life-science commercialisation company Eversana Life Science Services LLC. Will expand commercial footprint for diabetic kidney disease prognostic device KidneyIntelX. Device aims to help clinicians better predict chronic kidney disease in adult type 2 diabetes patients. Companies will provide field deployment and training to primary care providers across key US regions this summer, complimenting Renalytix's existing sales efforts in major markets including New York. Renalytix says two large clinical utility studies have shown the product helps clinicians better understand risks to patients, resulting in improved medication use and faster specialist referrals. Expects additional data on the product's real-world utility to be released next month at the American Diabetes Association annual clinical meeting. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Renalytix PLC on Wednesday hailed the results of a new independent review, which it said demonstrated the utility of KidneyIntelX in diagnosing patients with kidney disease and diabetes. Read More
Renalytix PLC - London-based kidney health-focused diagnostics company - Says that two scientific presentations proving the utility of KidneyIntelX in minorities and veterans have been accepted at the upcoming National Kidney Foundation Spring Clinicals Conference taking place in Austin, Texas. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More